Cargando…

Integrating Monitoring of Volume Status and Blood Volume-Controlled Ultrafiltration into Extracorporeal Kidney Replacement Therapy

PURPOSE: Volume management in hemodialysis (HD) requires the ability to assess volume status objectively and determine treatment strategies that achieve euvolemia without compromising hemodynamic stability. The aim of this study was to compare dialysis with and without blood volume-controlled ultraf...

Descripción completa

Detalles Bibliográficos
Autores principales: Zschätzsch, Sebastian, Stauss-Grabo, Manuela, Gauly, Adelheid, Braun, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416185/
https://www.ncbi.nlm.nih.gov/pubmed/34511978
http://dx.doi.org/10.2147/IJNRD.S319911
_version_ 1783748127471173632
author Zschätzsch, Sebastian
Stauss-Grabo, Manuela
Gauly, Adelheid
Braun, Jennifer
author_facet Zschätzsch, Sebastian
Stauss-Grabo, Manuela
Gauly, Adelheid
Braun, Jennifer
author_sort Zschätzsch, Sebastian
collection PubMed
description PURPOSE: Volume management in hemodialysis (HD) requires the ability to assess volume status objectively and determine treatment strategies that achieve euvolemia without compromising hemodynamic stability. The aim of this study was to compare dialysis with and without blood volume-controlled ultrafiltration (UF) in combination with body composition monitoring, and to evaluate indicators for adequate dialysis (Kt/V), ultrafiltration volume, fluid status, and the occurrence of intradialytic morbid events (IME). PATIENTS AND METHODS: Patients undergoing hemodialysis or on-line hemodiafiltration with support of a blood volume monitor (BVM) – a feedback control device integrated into the 5008 and 6008 HD systems – were enrolled. Patients received treatment for four weeks using the 6008 CAREsystem and the BVM (6008+). Data on dialysis dose (Kt/V), UF volume and predialysis fluid status were documented. This data was also documented retrospectively for four weeks with (5008+) and without (5008−) the use of the BVM with the 5008 system. Comparisons were analyzed using linear mixed models. RESULTS: Twenty-four patients were enrolled. Kt/V was unaffected by blood volume-controlled UF (5008− vs 5008+: p=0.230) and was equally achieved with both HD systems (5008+ vs 6008+: p=0.922). The UF volume and fluid status achieved were comparable, independent of the use of UF control with BVM (5008− vs 5008+; UF volume: p=0.166; fluid overload: p=0.390) or the HD system (5008+ vs 6008+: UF volume: p=0.003; fluid overload: p=0.838), except for UF volume being higher in the 6008+ phase. IMEs occurred in less than 3% of treatments, with no difference between study phases. CONCLUSION: This study demonstrates that a clinical approach to kidney replacement therapy that tracks volume status and manages intradialytic fluid removal by blood volume-controlled UF delivers adequate dialysis without compromising fluid removal. It maintains volume status and ensures low incidence of IMEs.
format Online
Article
Text
id pubmed-8416185
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84161852021-09-09 Integrating Monitoring of Volume Status and Blood Volume-Controlled Ultrafiltration into Extracorporeal Kidney Replacement Therapy Zschätzsch, Sebastian Stauss-Grabo, Manuela Gauly, Adelheid Braun, Jennifer Int J Nephrol Renovasc Dis Original Research PURPOSE: Volume management in hemodialysis (HD) requires the ability to assess volume status objectively and determine treatment strategies that achieve euvolemia without compromising hemodynamic stability. The aim of this study was to compare dialysis with and without blood volume-controlled ultrafiltration (UF) in combination with body composition monitoring, and to evaluate indicators for adequate dialysis (Kt/V), ultrafiltration volume, fluid status, and the occurrence of intradialytic morbid events (IME). PATIENTS AND METHODS: Patients undergoing hemodialysis or on-line hemodiafiltration with support of a blood volume monitor (BVM) – a feedback control device integrated into the 5008 and 6008 HD systems – were enrolled. Patients received treatment for four weeks using the 6008 CAREsystem and the BVM (6008+). Data on dialysis dose (Kt/V), UF volume and predialysis fluid status were documented. This data was also documented retrospectively for four weeks with (5008+) and without (5008−) the use of the BVM with the 5008 system. Comparisons were analyzed using linear mixed models. RESULTS: Twenty-four patients were enrolled. Kt/V was unaffected by blood volume-controlled UF (5008− vs 5008+: p=0.230) and was equally achieved with both HD systems (5008+ vs 6008+: p=0.922). The UF volume and fluid status achieved were comparable, independent of the use of UF control with BVM (5008− vs 5008+; UF volume: p=0.166; fluid overload: p=0.390) or the HD system (5008+ vs 6008+: UF volume: p=0.003; fluid overload: p=0.838), except for UF volume being higher in the 6008+ phase. IMEs occurred in less than 3% of treatments, with no difference between study phases. CONCLUSION: This study demonstrates that a clinical approach to kidney replacement therapy that tracks volume status and manages intradialytic fluid removal by blood volume-controlled UF delivers adequate dialysis without compromising fluid removal. It maintains volume status and ensures low incidence of IMEs. Dove 2021-08-30 /pmc/articles/PMC8416185/ /pubmed/34511978 http://dx.doi.org/10.2147/IJNRD.S319911 Text en © 2021 Zschätzsch et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zschätzsch, Sebastian
Stauss-Grabo, Manuela
Gauly, Adelheid
Braun, Jennifer
Integrating Monitoring of Volume Status and Blood Volume-Controlled Ultrafiltration into Extracorporeal Kidney Replacement Therapy
title Integrating Monitoring of Volume Status and Blood Volume-Controlled Ultrafiltration into Extracorporeal Kidney Replacement Therapy
title_full Integrating Monitoring of Volume Status and Blood Volume-Controlled Ultrafiltration into Extracorporeal Kidney Replacement Therapy
title_fullStr Integrating Monitoring of Volume Status and Blood Volume-Controlled Ultrafiltration into Extracorporeal Kidney Replacement Therapy
title_full_unstemmed Integrating Monitoring of Volume Status and Blood Volume-Controlled Ultrafiltration into Extracorporeal Kidney Replacement Therapy
title_short Integrating Monitoring of Volume Status and Blood Volume-Controlled Ultrafiltration into Extracorporeal Kidney Replacement Therapy
title_sort integrating monitoring of volume status and blood volume-controlled ultrafiltration into extracorporeal kidney replacement therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416185/
https://www.ncbi.nlm.nih.gov/pubmed/34511978
http://dx.doi.org/10.2147/IJNRD.S319911
work_keys_str_mv AT zschatzschsebastian integratingmonitoringofvolumestatusandbloodvolumecontrolledultrafiltrationintoextracorporealkidneyreplacementtherapy
AT staussgrabomanuela integratingmonitoringofvolumestatusandbloodvolumecontrolledultrafiltrationintoextracorporealkidneyreplacementtherapy
AT gaulyadelheid integratingmonitoringofvolumestatusandbloodvolumecontrolledultrafiltrationintoextracorporealkidneyreplacementtherapy
AT braunjennifer integratingmonitoringofvolumestatusandbloodvolumecontrolledultrafiltrationintoextracorporealkidneyreplacementtherapy